These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1203 related articles for article (PubMed ID: 34484235)

  • 1. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
    Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
    Front Immunol; 2021; 12():725223. PubMed ID: 34484235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
    Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
    Front Immunol; 2021; 12():791924. PubMed ID: 34975891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
    Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
    Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
    [No Abstract]   [Full Text] [Related]  

  • 4. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
    Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
    Front Immunol; 2022; 13():965469. PubMed ID: 36090967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF Family-Based Signature Predicts Prognosis, Tumor Microenvironment, and Molecular Subtypes in Bladder Carcinoma.
    Li H; Liu S; Li C; Xiao Z; Hu J; Zhao C
    Front Cell Dev Biol; 2021; 9():800967. PubMed ID: 35174161
    [No Abstract]   [Full Text] [Related]  

  • 6.
    Zhao X; Hu J; Li J; Gu L; Chen J; Othmane B; Gong G; Yuan J; Deng H
    Dis Markers; 2022; 2022():7147279. PubMed ID: 35909893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
    Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
    Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
    Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
    Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.
    Hu J; Othmane B; Yu A; Li H; Cai Z; Chen X; Ren W; Chen J; Zu X
    BMC Med; 2021 Nov; 19(1):289. PubMed ID: 34836536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TCGA Database-Based Screening of Tumor Microenvironment Immunomodulators Related to Bladder Cancer Prognosis.
    Ye JN; Gan MP; Wu XL; Dong Z; Mai HH
    Ann Clin Lab Sci; 2024 May; 54(3):299-312. PubMed ID: 39048164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer.
    Zheng X; Xu H; Lin T; Tan P; Xiong Q; Yi X; Qiu S; Yang L; Shen B; Ai J; Wei Q
    Comput Biol Med; 2022 Aug; 147():105727. PubMed ID: 35785664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
    Mo Z; Liu D; Rong D; Zhang S
    Front Immunol; 2021; 12():611058. PubMed ID: 33679749
    [No Abstract]   [Full Text] [Related]  

  • 14. FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.
    Xu PH; Chen S; Wang Y; Jin S; Wang J; Ye D; Zhu X; Shen Y
    Comput Biol Med; 2023 Aug; 162():106976. PubMed ID: 37301098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 4-gene-based hypoxia signature is associated with tumor immune microenvironment and predicts the prognosis of pancreatic cancer patients.
    Ding J; He X; Cheng X; Cao G; Chen B; Chen S; Xiong M
    World J Surg Oncol; 2021 Apr; 19(1):123. PubMed ID: 33865399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

  • 18. An EMT-based risk score thoroughly predicts the clinical prognosis, tumor immune microenvironment and molecular subtypes of bladder cancer.
    Xiao Z; Cai Z; Deng D; Tong S; Zu X
    Front Immunol; 2022; 13():1000321. PubMed ID: 36211349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Natural Killer Cell-related Gene Signature for Improving the Prediction of Prognosis and Immunotherapy Response in Bladder Cancer.
    Ma X; Wei X; Yang G; Li S; Liu R
    Comb Chem High Throughput Screen; 2024; 27(8):1205-1221. PubMed ID: 37653625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel focal adhesion-related risk model predicts prognosis of bladder cancer -- a bioinformatic study based on TCGA and GEO database.
    Hu J; Wang L; Li L; Wang Y; Bi J
    BMC Cancer; 2022 Nov; 22(1):1158. PubMed ID: 36357874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.